About 10 million Americans suffer several degree of vision loss cause by age-related macular degeneration, and that figure is predictable to grow as more baby boomers become senior citizens. There is no cure for the disease, but last week the U.S. Food and Drug Administration give a green light to an abnormal clinical trial that seeks to restore patients' view by employing human embryonic stem cells. None of the stem cells will be inject into patients; instead, they are grown into a different kind of cell that will be deliver to the back of the eye, where the retina is injured by the disease. The hope is that the cells will help mend the damaged retinal tissue.
The company behind the test, Santa Monica base superior Cell Technology Inc., developed the therapy to treat Stargardt's macular dystrophy, a rare childhood account of macular degeneration that affect about 1 in 10,000 kids. The FDA gave the company authorization to test the therapy in Stargardt's patients in November. However, if they work, the cells would have a much larger result as a treatment for age connected macular degeneration.
The company behind the test, Santa Monica base superior Cell Technology Inc., developed the therapy to treat Stargardt's macular dystrophy, a rare childhood account of macular degeneration that affect about 1 in 10,000 kids. The FDA gave the company authorization to test the therapy in Stargardt's patients in November. However, if they work, the cells would have a much larger result as a treatment for age connected macular degeneration.
No comments:
Post a Comment